Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC)

Federico Cappuzzo, Andrea Ardizzoni, Hector Soto-Parra, Cesare Gridelli, Paolo Maione, Marcello Tiseo, Cesare Calandri, Stefania Bartolini, Armando Santoro, Lucio Crinò

Research output: Contribution to journalArticle

Abstract

Purpose: We report four cases of Brain Metastases (BM) from non-small cell lung cancer (NSCLC) responding to ZD 1839 therapy after standard therapy failure. Patients and methods: Four patients with BM from NSCLC, pretreated with two or more lines of chemotherapy, received ZD 1839 (Iressa), on a compassionate use basis, at the daily dose of 250 mg until disease progression. Three patients received Iressa after whole brain radiotherapy (WBRT) failure. Results: After 3 months of ZD 1839 therapy, one patient had complete response on the brain with stabilization of extracranial disease, while the other three patients had partial response both on the brain and on extracranial sites. At the time of this analysis, two patients discontinued the treatment after 5 and 7 months for disease progression, while two patients are still on treatment with no evidence of treatment failure after 3+ and 12+ months. ZD 1839 was generally well tolerated, with skin toxicity recorded in two patients. Conclusion: ZD 1839 may be effective in NSCLC patients with pretreated BM. Large and prospective trials need to clarify the role of ZD 1839 in the treatment of BM from NSCLC.

Original languageEnglish
Pages (from-to)227-231
Number of pages5
JournalLung Cancer
Volume41
Issue number2
DOIs
Publication statusPublished - Aug 1 2003

Keywords

  • Non-small cell lung cancer
  • Thyrosine kinase inhibitor
  • ZD 1839

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC)'. Together they form a unique fingerprint.

  • Cite this

    Cappuzzo, F., Ardizzoni, A., Soto-Parra, H., Gridelli, C., Maione, P., Tiseo, M., Calandri, C., Bartolini, S., Santoro, A., & Crinò, L. (2003). Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC). Lung Cancer, 41(2), 227-231. https://doi.org/10.1016/S0169-5002(03)00189-2